Roche $4.8bn Buy Sparks Hemophilia Gene Therapy Race
Executive Summary
The Swiss major's proposed acquisition of Spark Therapeutics gives it a leading seat at the table in the emerging field of gene therapy.
You may also be interested in...
Gene Therapy: What To Expect Now And In The Future
The US FDA could approve as many new gene therapies in 2023 as it has in the previous five years. Development in the field has rapidly accelerated, but still faces hurdles.
Round Two: BioMarin Resubmits Hemophilia A Gene Therapy Roctavian In US
BioMarin maintains its lead in the race to win approval for a hemophilia A gene therapy in the US by resubmitting Roctavian two years after the FDA issued a CRL in response to the original BLA.
Pharma Spreads Its Bets On Multiple Modalities In Advanced Products
Companies such as Novartis, Roche or Takeda are heavily invested in the advanced therapeutics field, usually spreading their bets across multiple modalities. The remaining challenges offer opportunities for the next wave of innovation to transform the field once again and make a dent in the larger market of common diseases and solid tumors.